OncoMatch/Clinical Trials/NCT05806060
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Is NCT05806060 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including VEGFR and TPC and TPC for triple-negative breast cancer.
Treatment: VEGFR and TPC · TPC — The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) absence of expression
absence of HER2, ER, and PR expression
Required: ESR1 absence of expression
absence of HER2, ER, and PR expression
Required: PR (PGR) absence of expression
absence of HER2, ER, and PR expression
Disease stage
Required: Stage IV
Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: no previous chemotherapy for metastatic triple-negative breast cancer
Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
Cannot have received: targeted therapy
Exception: no previous targeted therapy for metastatic triple-negative breast cancer
Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
Lab requirements
Blood counts
The functions of major organs are basically normal
Kidney function
The functions of major organs are basically normal; Urine protein ≥2+ and 24h urine protein quantitative > 1.0 g [excluded]
Liver function
The functions of major organs are basically normal; Patients with known active HBV or HCV infection or hepatitis B DNA≥500, or chronic phase with abnormal liver function [excluded]
Cardiac function
Significant cardiovascular disease [excluded]
The functions of major organs are basically normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify